Dopamine Justice Alliance fights for victims devastated by dopamine agonist drugs like pramipexole and ropinirole, exposing hidden impulse control disorders that wrecked lives without adequate warnings.
Born from the tragedy of Alan John Williams—whose dopamine agonist medication unleashed sugar binges (up to 1kg+/day), substantial investment losses, between 50 and 100 infections, dozens of emergency hospitalisations (nearly 1 year inpatient 2015–2023), and a disputed 2017 vascular dementia label amid preserved capacity—the Alliance demands accountability from manufacturers (GSK, Boehringer Ingelheim) and NHS prescribers.
It provides emotional support, connects families, intends to fund legal action via CrowdJustice, and raises awareness of compulsions (binge eating, gambling, hypersexuality) amplified in vulnerable groups like those with kidney issues.
Public data suggest that many tens of thousands of people in the UK are prescribed dopamine agonists at any one time, with English prescribing rates alone around 190 dopamine‑agonist prescriptions per 100,000 population between 2019 and 2024. Studies in Parkinson’s populations consistently find impulse control disorders in roughly 10–17% of those on dopamine agonists, which, applied cautiously to current UK usage, implies that many thousands of patients are likely to have been directly affected by compulsive side effects, and tens of thousands more family members and close contacts indirectly impacted by financial collapse, relationship breakdown, safeguarding issues and unresolved grief.pmc.ncbi.nlm.nih+1

Dad's 48-hour dietary intake
Dopamine Justice Alliance